Drug intelligence / Profile preview

MTDX401

Development stage: Preclinical
Lead developer: Montdorex
Modality: Small Molecules
Administration: Unspecified (preclinical/early Research Phase)[1]

Overview

MTDX401 is a pentamidine analogue classified as an amidine and small molecule hepatoprotectant. It is being developed by Montdorex for the treatment of gastrointestinal disorders and liver disorders. The drug acts as an immunomodulator, with its mechanism of action involving modulation of immune responses. As a new molecular entity, it represents a novel approach within its class for these indications[1].

Beyond the preview

Go deeper on MTDX401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTDX401.

Explore the full profile